CA2526217A1 - Heteroaryl-fused pyrimidinyl compounds as anticancer agents - Google Patents

Heteroaryl-fused pyrimidinyl compounds as anticancer agents Download PDF

Info

Publication number
CA2526217A1
CA2526217A1 CA002526217A CA2526217A CA2526217A1 CA 2526217 A1 CA2526217 A1 CA 2526217A1 CA 002526217 A CA002526217 A CA 002526217A CA 2526217 A CA2526217 A CA 2526217A CA 2526217 A1 CA2526217 A1 CA 2526217A1
Authority
CA
Canada
Prior art keywords
compound
substituted
hydrogen
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002526217A
Other languages
English (en)
French (fr)
Inventor
Weibo Wang
Liana M. Lagniton
Ryan N. Constantine
Matthew T. Burger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2526217A1 publication Critical patent/CA2526217A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA002526217A 2003-05-30 2004-05-27 Heteroaryl-fused pyrimidinyl compounds as anticancer agents Abandoned CA2526217A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47468403P 2003-05-30 2003-05-30
US60/474,684 2003-05-30
PCT/US2004/016954 WO2004111058A1 (en) 2003-05-30 2004-05-27 Heteroryl-fused pyrimidinyl compounds as anticancer agents

Publications (1)

Publication Number Publication Date
CA2526217A1 true CA2526217A1 (en) 2004-12-23

Family

ID=33551504

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002526217A Abandoned CA2526217A1 (en) 2003-05-30 2004-05-27 Heteroaryl-fused pyrimidinyl compounds as anticancer agents

Country Status (10)

Country Link
US (2) US7345046B2 (https=)
EP (1) EP1636238A1 (https=)
JP (1) JP2007500237A (https=)
KR (1) KR20060054187A (https=)
CN (1) CN100418971C (https=)
AU (1) AU2004247650A1 (https=)
CA (1) CA2526217A1 (https=)
MX (1) MXPA05012706A (https=)
TW (1) TW200505454A (https=)
WO (1) WO2004111058A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
NZ542227A (en) * 2003-03-07 2008-12-24 Astrazeneca Ab Novel fused heterocycles and uses thereof
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
RU2006138864A (ru) * 2004-04-06 2008-05-20 Чирон Корпорейшн (Us) Ингибиторы митотического кинезина
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
WO2006008523A1 (en) * 2004-07-22 2006-01-26 Astrazeneca Ab Fused pyrimidones usefuel in the treatment and the prevention of cancer
WO2006023931A2 (en) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
KR20070046175A (ko) * 2004-08-18 2007-05-02 아스트라제네카 아베 선택된 융합 복소환 및 이의 용도
EP1781674A1 (en) * 2004-08-18 2007-05-09 AstraZeneca AB Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer
EP1812439B2 (en) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1863571A1 (en) * 2005-03-09 2007-12-12 Shering Corporation Compounds for inhibiting ksp kinesin activity
JP2008533018A (ja) * 2005-03-09 2008-08-21 シェーリング コーポレイション ＫＳＰキネシン活性を阻害するための縮合チエノ［２，３−ｂ］ピリジン化合物および縮合チアゾロ［５，４−ｂ］ピリジン化合物
US7608643B2 (en) 2005-03-09 2009-10-27 Schering Corporation Compounds for inhibiting KSP kinesin activity
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
AU2011205048B2 (en) * 2005-05-13 2013-05-02 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
WO2006119646A1 (en) 2005-05-13 2006-11-16 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
EP2131849B1 (en) * 2007-03-02 2011-10-26 The University Of Wollongong Compositions and methods for delivery of anti-cancer agents
WO2008147852A1 (en) * 2007-05-22 2008-12-04 Taigen Biotechnology Co., Ltd. Kinesin inhibitors
KR20100024494A (ko) 2007-06-22 2010-03-05 아르퀼 인코포레이티드 퀴나졸리논 화합물 및 이의 사용 방법
AR069869A1 (es) * 2007-12-21 2010-02-24 Exelixis Inc Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112017014264A2 (pt) * 2014-12-29 2018-03-06 V Kornienko Alexander Análogos de rigidina sintética como agentes anti- câncer, sais, solvatos e pró-fármacos destes, e método de produção destes
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720969B2 (ja) * 1988-03-02 1995-03-08 吉富製薬株式会社 ３，４―ジヒドロチエノ〔２，３―ｄ〕ピリミジン化合物およびその医薬用途
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
JP2005511581A (ja) 2001-11-07 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
JP2005515208A (ja) 2001-12-06 2005-05-26 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂性キネシン阻害剤
WO2003049527A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2468156A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Azolopyrimidinone compounds and their use
CA2467722A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Thienopyrimidinone derivatives as mitotic kinesin inhibitors
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1517904A4 (en) 2002-05-23 2007-02-21 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
WO2004034972A2 (en) 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods

Also Published As

Publication number Publication date
EP1636238A1 (en) 2006-03-22
CN100418971C (zh) 2008-09-17
KR20060054187A (ko) 2006-05-22
MXPA05012706A (es) 2006-02-08
WO2004111058A1 (en) 2004-12-23
CN1798749A (zh) 2006-07-05
US20080069817A1 (en) 2008-03-20
JP2007500237A (ja) 2007-01-11
US20050065169A1 (en) 2005-03-24
US7345046B2 (en) 2008-03-18
AU2004247650A1 (en) 2004-12-23
TW200505454A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
CA2526217A1 (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
EP1636225B1 (en) Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents
EP1689724B1 (en) Quinazolinone compounds as anticancer agents
US7855295B2 (en) Tetrahydrocarboline compounds as anticancer agents
JP2007500237A5 (https=)
JP2007512368A5 (https=)
AU2006236557A1 (en) 2-amino-quinazolin-5-ones as HSP90 inhibitors useful in treating proliferation diseases
MXPA06005844A (en) Quinazolinone compounds as anticancer agents

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued